Repurposing Nucleoside Analogs for Human Coronaviruses

Coronavirus disease 2019 (COVID-19) is a serious illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or CoV-2). Some reports claimed certain nucleoside analogs to be active against CoV-2 and thus needed confirmation. Here, we evaluated a panel of compounds and identified no...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Antimicrobial agents and chemotherapy Ročník 65; číslo 1
Hlavní autori: Zandi, Keivan, Amblard, Franck, Musall, Katie, Downs-Bowen, Jessica, Kleinbard, Ruby, Oo, Adrian, Cao, Dongdong, Liang, Bo, Russell, Olivia O, McBrayer, Tamara, Bassit, Leda, Kim, Baek, Schinazi, Raymond F
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States 16.12.2020
Predmet:
Animals
Antiviral Agents - chemistry
Antiviral Agents - pharmacology
Antiviral Agents - toxicity
Cell Line
Chlorocebus aethiops
Coronavirus OC43, Human - drug effects
Drug Evaluation, Preclinical
Drug Repositioning - methods
Humans
Nucleosides - chemistry
Nucleosides - pharmacology
Nucleosides - toxicity
Propanolamines - pharmacology
SARS-CoV-2 - drug effects
Sofosbuvir - pharmacology
Vero Cells
COVID-19
sofosbuvir
emtricitabine
SARS-CoV-2
nucleoside analogs
antiviral agents
Coronaviridae
remdesivir
HCoV-OC43
lamivudine
ISSN:1098-6596, 1098-6596
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Coronavirus disease 2019 (COVID-19) is a serious illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or CoV-2). Some reports claimed certain nucleoside analogs to be active against CoV-2 and thus needed confirmation. Here, we evaluated a panel of compounds and identified novel nucleoside analogs with antiviral activity against CoV-2 and HCoV-OC43 while ruling out others. Of significance, sofosbuvir demonstrated no antiviral effect against CoV-2, and its triphosphate did not inhibit CoV-2 RNA polymerase.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1098-6596
1098-6596
DOI:10.1128/AAC.01652-20